TD Cowen Maintains Outperform on Boston Scientific, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joshua Jennings has reaffirmed an Outperform rating on Boston Scientific (NYSE:BSX) and increased the price target from $58 to $65, indicating a positive outlook on the company's stock.
December 12, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Joshua Jennings has maintained an Outperform rating on Boston Scientific and raised the price target to $65, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst typically signals a bullish outlook on the stock, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100